March 8, 2018 VACCIBODY AS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION (CTA) FOR ITS CANCER NEOANTIGEN PHASE I/IIA TRIAL BY GERMAN REGULATORY AUTHORITIES (PAUL EHRLICH INSTITUTE (PEI)).
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)). Dr. Martin Bonde, Chief Executive Officer...